LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)

被引：0
|
作者：
Sandhu, Shahneen
Joshua, Anthony M.
Emmett, Louise
Crumbaker, Megan
Bressel, Mathias
Huynh, Rhonda
Banks, Patricia Diana
Wallace, Roslyn
Hamid, Anis
Inderjeeth, Andrisha Jade
Tran, Ben
Azad, Arun
Alipour, Ramin
Kong, Grace
Kumar, Aravind Ravi
Saghebi, Javad
Williams, Scott
Akhurst, Timothy J.
Hicks, Rodney J.
Hofman, Michael S.
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] St Vincents Hosp, Sydney, NSW, Australia
[4] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[7] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, Melbourne, Vic, Australia
[8] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[9] Univ Melbourne, St Vincents Med Sch, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5005
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [22] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [23] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [24] Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Braeuer, Axel
    Yordanova, Anna
    Boegemann, Martin
    Hauser, Stefan
    Eveslage, Maria
    Essler, Markus
    Schafers, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [25] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Fadi Khreish
    Niklas Kochems
    Florian Rosar
    Amir Sabet
    Martin Ries
    Stephan Maus
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112
  • [26] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Khreish, Fadi
    Kochems, Niklas
    Rosar, Florian
    Sabet, Amir
    Ries, Martin
    Maus, Stephan
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 103 - 112
  • [27] Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Batra, Jaspreet
    Christos, Paulj.
    Jhanwar, Yuliya
    Goldsmith, Stanley J.
    Nanus, David M.
    Beltran, Himisha
    Molina, Ana M.
    Faltas, Bishoy
    Hackett, Amy
    Sreekumar, Jyothi
    Babich, John
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Niaz, Muhammad Junaid
    Osborne, Joseph
    Vallabhajosula, Shankar
    Beltran, Himisha
    Harshman, Lauren Christine
    Nanus, David M.
    Molina, Ana M.
    Faltas, Bishoy Morris
    Hackett, Amy
    Gracey, Lauren
    Sreekumar, Jyothi
    Babich, John
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [29] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [30] Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Boegeman, Martin
    Yordanova, Anna
    Eveslage, Maria
    Schaefers, Michael
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (02) : 243 - 246
12345